ICU-acquired muscle weakness in COVID-19 patients who underwent lung transplantation

doi:10.5847/wjem.j.1920-8642.2025.006

World Journal of Emergency Medicine ›› 2025, Vol. 16 ›› Issue (1): 94-96.doi: 10.5847/wjem.j.1920-8642.2025.006

• Case Letters • Previous Articles Next Articles

ICU-acquired muscle weakness in COVID-19 patients who underwent lung transplantation

Juan Chen¹^,²^,⁴, Bingqing Yue²^,³^,⁴, Jingyu Chen²^,³^,⁴^,⁵(), Man Huang¹^,²^,³^,⁴()

¹General Intensive Care Unit, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310014, China
²Lung Transplantation Laboratory, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310014, China
³Department of Lung Transplantation, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310014, China
⁴Key Laboratory of Multiple Organ Failure (Zhejiang University), Ministry of Education, Hangzhou 310014, China
⁵Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi 214043, China

Received:2024-06-10 Accepted:2024-10-26 Online:2025-01-23 Published:2025-01-01
Contact: Jingyu Chen,Man Huang E-mail:chenjy@wuxiph.com;huangman@zju.edu.cn

Abstract

Juan Chen, Bingqing Yue, Jingyu Chen, Man Huang. ICU-acquired muscle weakness in COVID-19 patients who underwent lung transplantation[J]. World Journal of Emergency Medicine, 2025, 16(1): 94-96.

Figures/Tables 3

Table 1.

Figure 1.

Figure 2.

References 10

1	Harris E. Lung transplants for COVID-19 similarly successful. JAMA. 2023; 330(10):906.
2	van Aerde N, van den Berghe G, Wilmer A, Gosselink R, Hermans G, Consortium C. Intensive care unit-acquired muscle weakness in COVID-19 patients. Intensive Care Med. 2020; 46(11):2083-5.
3	Bharat A, Machuca TN, Querrey M, Kurihara C, Garza-Castillon R Jr, Kim S, et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir Med. 2021; 9(5):487-97. doi: 10.1016/S2213-2600(21)00077-1 pmid: 33811829
4	Han XY, Fan YQ, Alwalid O, Li N, Jia X, Yuan M, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. 2021 ;299(1): E177-E186.
5	Chen J, Huang M. Intensive care unit-acquired weakness: recent insights. J Intensive Med. 2023; 4(1):73-80.
6	Wang Q, Pan SB, Zhang S, Shen G, Huang M, Wu M. Lung transplantation in pulmonary fibrosis secondary to influenza A pneumonia. Ann Thorac Surg. 2019 ;108(4):e233-e235.
7	Huang M, Xu YS, Yan S, Shi YJ, Pan SB, Chen YB, et al. Use of veno-arterial extracorporeal membrane oxygenation ian the first successful combined lung-liver transplantation patient in China. World J Emerg Med. 2022; 13(5):412-4. doi: 10.5847/wjem.j.1920-8642.2022.090 pmid: 36119762
8	Chen XY, Lei X, Xu X, Zhou Y, Huang M. Intensive care unit-acquired weakness in patients with extracorporeal membrane oxygenation support: frequency and clinical characteristics. Front Med (Lausanne). 2022; 9:792201.
9	Vanhorebeek I, Latronico N, van den Berghe G. ICU-acquired weakness. Intensive Care Med. 2020; 46(4):637-53. doi: 10.1007/s00134-020-05944-4 pmid: 32076765
10	Patel BK, Wolfe KS, Patel SB, Dugan KC, Esbrook CL, Pawlik AJ, et al. Effect of early mobilisation on long-term cognitive impairment in critical illness in the USA: a randomised controlled trial. Lancet Respir Med. 2023; 11(6):563-72. doi: 10.1016/S2213-2600(22)00489-1 pmid: 36693400

Clinical characteristics	Patient 1	Patient 2
Gender	Male	Male
Age, years	59	61
Body Mass Index	22.5	23.3
Charlson Comorbidity Index score	4	3
Primary disease	Severe pneumonia	Severe pneumonia
Transplant type	Bilateral	Bilateral
Duration of supportive therapy
MV duration, d	136	23
MV duration before lung transplantation, d	131	15
ECMO duration, d	131	16
ECMO duration before lung transplantation, d	130	15
Drugs
Glucocorticoid (duration^a, d)	Yes (146)	Yes (57)
Norepinephrine	Yes	Yes
Adrenaline	Yes	No
NMBAs	Yes	Yes
Time and depth of sedation^a
Sedation duration, h	670.5	291.5
Deep sedation duration, h	9.5	192.5
Light sedation duration, h	661	99
Blood glucose range ^a, mmol/L	5.4-24.1	5.3-13.0
Duration of ICU-AW ^a, d	112	34
APACHE II score	18	23
Medical Research Council score	18	24
Length of ICU stay, d	256	45
Length of hospital stay, d	290	84
Donor	DBD	DBD
Ischemic time of left lung, h	7.38	6.33
Ischemic time of right lung, h	6.48	4.78

ICU-acquired muscle weakness in COVID-19 patients who underwent lung transplantation

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 10

Related Articles 0

Recommended Articles

Comments